QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:ARAV

Aravive (ARAV) Stock Forecast, Price & News

$1.70
+0.07 (+4.29%)
(As of 05/31/2023 ET)
Compare
Today's Range
$1.56
$1.73
50-Day Range
$1.42
$2.30
52-Week Range
$0.58
$2.46
Volume
486,826 shs
Average Volume
253,528 shs
Market Capitalization
$101.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Aravive MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
441.2% Upside
$9.20 Price Target
Short Interest
Bearish
7.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.74mentions of Aravive in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.26) to ($1.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

687th out of 1,006 stocks

Pharmaceutical Preparations Industry

350th out of 492 stocks


ARAV stock logo

About Aravive (NASDAQ:ARAV) Stock

Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
7 Short-Interest Stocks to Target for Explosive Gains
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Recap: Aravive Q1 Earnings
Aravive (ARAV) to Release Quarterly Earnings on Wednesday
What Makes Aravive (ARAV) a New Buy Stock
BTIG Keeps Their Buy Rating on Aravive (ARAV)
Aravive, Inc. (NASDAQ:ARAV) Short Interest Up 16.0% in March
See More Headlines
Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Company Calendar

Last Earnings
3/15/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARAV
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.20
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+421.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-76,320,000.00
Net Margins
-1,187.30%
Pretax Margin
-1,187.30%

Debt

Sales & Book Value

Annual Sales
$9.14 million
Book Value
($0.65) per share

Miscellaneous

Free Float
23,938,000
Market Cap
$97.56 million
Optionable
Optionable
Beta
2.35

Key Executives

  • Gail Frances McIntyreGail Frances McIntyre
    President, Chief Executive Officer & Director
  • Leonard Scott Dove
    Chief Operating Officer
  • Rudy C. Howard
    Chief Financial & Accounting Officer
  • Robert B. Geller
    Chief Medical Officer
  • Maria Carolina Petrini
    Chief Commercial Officer













ARAV Stock - Frequently Asked Questions

Should I buy or sell Aravive stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARAV shares.
View ARAV analyst ratings
or view top-rated stocks.

What is Aravive's stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price targets for Aravive's stock. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they expect the company's stock price to reach $9.20 in the next year. This suggests a possible upside of 464.4% from the stock's current price.
View analysts price targets for ARAV
or view top-rated stocks among Wall Street analysts.

How have ARAV shares performed in 2023?

Aravive's stock was trading at $1.32 at the beginning of the year. Since then, ARAV stock has increased by 23.5% and is now trading at $1.63.
View the best growth stocks for 2023 here
.

When is Aravive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ARAV earnings forecast
.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.13. The firm had revenue of $1.47 million for the quarter, compared to analyst estimates of $0.37 million. Aravive had a negative net margin of 1,187.30% and a negative trailing twelve-month return on equity of 1,865.78%.

What other stocks do shareholders of Aravive own?
What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.36%), BlackRock Inc. (0.35%), Assenagon Asset Management S.A. (0.33%), Two Sigma Advisers LP (0.27%), Renaissance Technologies LLC (0.26%) and Jane Street Group LLC (0.11%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends
.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $1.63.

How much money does Aravive make?

Aravive (NASDAQ:ARAV) has a market capitalization of $97.56 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.

This page (NASDAQ:ARAV) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -